Hajji Ahmed, Mhabrech Houda El, Daldoul Amira, Toumia Nada, Hajjaji Awatef, Njima Manel, Jebali Fethi, Faleh Raja
Service de Gynécologie Obstétrique, Centre de Maternité et de Néonatologie de Monastir, Centre Hospitalier Universitaire Fattouma Bourguiba Monastir, Université de Monastir, Monastir, Tunisie.
Service d´Imagerie Médicale, Hôpital Hadj Ali Soua, Ksar Hellal, Université de Monastir, Monastir, Tunisie.
Pan Afr Med J. 2021 Feb 17;38:180. doi: 10.11604/pamj.2021.38.180.23108. eCollection 2021.
The purpose of this study was to describe the clinical, radiological, histological and therapeutic features of breast cancer diagnosed during pregnancy. We performed a review of all medical records of patients with breast cancer diagnosed during pregnancy in the Maternity and Neonatal Center, Monastir-Tunisia, over the period 2004-2019. We collected data on 15 cases. The average age of patients was 34 years; most pregnancy-associated breast cancers (PABCs) had been diagnosed during the postpartum period. Invasive ductal carcinoma was the major histological type (93% of cases), a rare case of secretory breast carcinoma had been observed. The main clinical stages were T2 and T4 breast cancer. Hormone receptor (HR)-negative breast cancers had been reported in 40% of cases, HER2-positive breast cancers in 26.6% of cases. Treatment included surgery, radiotherapy, chemotherapy and palliative chemotherapy. The median overall survival was 32.2 months. Pregnancy-associated breast cancer is a rare entity. Patients' prognosis is generally poor due to the young age at onset and a usually delayed diagnosis. Patients should participate in therapeutic decision making, which is difficult and multidisciplinary. Targeted therapy is the great hope for new therapies.
本研究的目的是描述孕期诊断出的乳腺癌的临床、放射学、组织学和治疗特征。我们回顾了2004年至2019年期间突尼斯莫纳斯提尔母婴中心孕期诊断出的乳腺癌患者的所有病历。我们收集了15例患者的数据。患者的平均年龄为34岁;大多数妊娠相关乳腺癌(PABC)是在产后阶段诊断出的。浸润性导管癌是主要的组织学类型(93%的病例),观察到1例罕见的分泌性乳腺癌病例。主要临床分期为T2和T4期乳腺癌。40%的病例报告为激素受体(HR)阴性乳腺癌,26.6%的病例为HER2阳性乳腺癌。治疗包括手术、放疗、化疗和姑息化疗。中位总生存期为32.2个月。妊娠相关乳腺癌是一种罕见的疾病。由于发病年龄较轻且通常诊断延迟,患者的预后一般较差。患者应参与治疗决策,这一过程困难且需要多学科协作。靶向治疗是新疗法的巨大希望。